目的 探讨宫瘤清胶囊联合亮丙瑞林治疗围绝经期子宫肌瘤的临床疗效。方法 选取2017年2月—2018年1月在成都中医药大学附属医院进行治疗的84例围绝经期子宫肌瘤患者为研究对象，按照用药差别分为对照组和治疗组，每组各42例。对照组腹部皮下注射注射用醋酸亮丙瑞林缓释微球，于月经周期的第1天开始给药，3.75 mg/次，1次/4周；治疗组在对照组治疗基础上口服宫瘤清胶囊，3粒/次，3次/d。两组均经过3个月经周期治疗后进行效果评价。观察两组的临床疗效，比较两组治疗前后子宫体积、肌瘤体积、性激素水平、血清学指标的变化情况。结果 治疗后，对照组和治疗组的总有效率分别为80.95%、95.24%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者子宫体积、肌瘤体积均较治疗前显著缩小，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组子宫体积、肌瘤体积显著小于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组雌二醇（E₂）、孕酮（P）、促卵泡刺激素（FSH）、黄体生成素（LH）、血清人附睾蛋白4（HE4）、血管内皮生长因子（VEGF）、糖抗原125（CA125）水平均较治疗前显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组E₂、P、FSH、LH、HE4、VEGF、CA125水平低于对照组，两组比较差异有统计学意义（P<0.05）。结论 宫瘤清胶囊联合亮丙瑞林治疗围绝经期子宫肌瘤具有较好的临床疗效，可有效缩小子宫肌瘤体积，改善机体性激素水平，降低血清HE4、VEGF及CA125水平，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Gongliuqing Capsules combined with leuprorelin in treatment of perimenopausal uterine fibroids. Methods Patients (84 cases) with perimenopausal uterine fibroids in Affiliated Hospital of Chengdu University of Traditional Chinese Medicine from February 2017 to January 2018 were divided into control (42 cases) and treatment (42 cases) groups according to the difference of treatment. Patients in the control group were sc in abdomen administered with Leuprorelin Acetate Microspheres Sustained Release for injection, begins on the first day of the menstrual cycle, 3.75 mg/time, once four weeks. Patients in the treatment group were po administered with Gongliuqing Capsules, 3 grains/time, three times daily. Two groups were evaluated after 3 menstrual cycles. After treatment, the clinical efficacy was evaluated, and the changes of uterine volume, fibroid volume, sex hormone levels, and serological indicators in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment group were 80.95% and 95.24%, and there were differences between two groups (P < 0.05). After treatment, uterine volume and fibroid volume in two groups were significantly decreased, and there were differences in the same group (P < 0.05). After treatment, uterine volume and fibroid volume in the treatment group were smaller than those in the control group, and there were differences between two groups (P < 0.05). After treatment, the levers of E₂, P, FSH, LH, HE4, VEGF, and CA125 in two groups were significantly decreased, and there were differences in the same group (P < 0.05). After treatment, E₂, P, FSH, LH, HE4, VEGF, and CA125 in the treatment group were lower than those in the control group, and there were differences between two groups (P < 0.05). Conclusion Gongliuqing Capsules combined with leuprorelin has significant clinical effect in treatment of perimenopausal uterine fibroids, and can effectively reduce the uterine fibroids volume and improve the sex hormone levels, and can decrease serum levels of HE4, VEGF and CA125, which has a certain clinical application value.